Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study

Fredrick Wigley, Robert A Wise, James R. Seibold, Deborah A. McCloskey, Gregory Kujala, Thomas A. Medsger, Virginia D. Steen, John Varga, Sergio Jimenez, Maureen Mayes, Philip J. Clements, Steven R. Weiner, John Porter, Michael Ellman, Christopher Wise, Lee D. Kaufman, John Williams, William Dole

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate the efficacy and safety of iloprost, a prostacyclin analog, administered intravenously in patients with Raynaud phenomenon secondary to systemic sclerosis. Design: Multicenter, randomized, parallel placebocontrolled, double-blind study. ■ Setting: University medical centers. ■ Patients: 131 patients with systemic sclerosis (101 women, 30 men) ages 20 to 79 years. ■ Intervention: Patients were randomly assigned to receive one of two parallel treatments of five daily sequential, 6-hour intravenous infusions of iloprost (0.5 to 2.0 ng/kg per min) or to receive a similar volume of placebo. Measurements: Frequency of Raynaud attacks, Raynaud severity score, physician's overall rating of treatment effect, and digital cutaneous lesion healing. ■ Results: Of the 131 patients enrolled, 126 completed the 5-day infusion and 114 (87%) completed at least 6 weeks of follow-up. Sixty-four patients were randomly assigned to receive iloprost and 67 patients, to receive placebo. The mean weekly number of Raynaud attacks decreased 39.1% with iloprost and 22.2% with placebo (P= 0.005). In addition, the mean percentage of improvement in a global Raynaud severity score during the entire 9-week follow-up was greater in patients given iloprost (34.8%) than in those receiving placebo (19.7%) (P= 0.011). The physician's overall rating of treatment effect showed greater improvement with iloprost than with placebo at week 6 (52.4% compared with 27.4%; P = 0.008) and week 9 (60.9% compared with 26.9%; P <0.001). At week 3, 14.6% more patients receiving iloprost had 50% or more lesions heal compared with those given placebo (95% Cl, 0.9% to 30%). During the infusion, 59 (92%) of the patients receiving iloprost had one or more side effects compared with 38 (57%) of the patients receiving placebo. ■ Conclusion: iloprost is effective for the short-term palliation of severe Raynaud phenomenon in patients with systemic sclerosis.

Original languageEnglish (US)
Pages (from-to)199-206
Number of pages8
JournalAnnals of Internal Medicine
Volume120
Issue number3
StatePublished - Feb 1 1994

Fingerprint

Iloprost
Raynaud Disease
Systemic Scleroderma
Double-Blind Method
Intravenous Infusions
Placebos
Physicians
Epoprostenol

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis : A multicenter, placebo-controlled, double-blind study. / Wigley, Fredrick; Wise, Robert A; Seibold, James R.; McCloskey, Deborah A.; Kujala, Gregory; Medsger, Thomas A.; Steen, Virginia D.; Varga, John; Jimenez, Sergio; Mayes, Maureen; Clements, Philip J.; Weiner, Steven R.; Porter, John; Ellman, Michael; Wise, Christopher; Kaufman, Lee D.; Williams, John; Dole, William.

In: Annals of Internal Medicine, Vol. 120, No. 3, 01.02.1994, p. 199-206.

Research output: Contribution to journalArticle

Wigley, F, Wise, RA, Seibold, JR, McCloskey, DA, Kujala, G, Medsger, TA, Steen, VD, Varga, J, Jimenez, S, Mayes, M, Clements, PJ, Weiner, SR, Porter, J, Ellman, M, Wise, C, Kaufman, LD, Williams, J & Dole, W 1994, 'Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study', Annals of Internal Medicine, vol. 120, no. 3, pp. 199-206.
Wigley, Fredrick ; Wise, Robert A ; Seibold, James R. ; McCloskey, Deborah A. ; Kujala, Gregory ; Medsger, Thomas A. ; Steen, Virginia D. ; Varga, John ; Jimenez, Sergio ; Mayes, Maureen ; Clements, Philip J. ; Weiner, Steven R. ; Porter, John ; Ellman, Michael ; Wise, Christopher ; Kaufman, Lee D. ; Williams, John ; Dole, William. / Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis : A multicenter, placebo-controlled, double-blind study. In: Annals of Internal Medicine. 1994 ; Vol. 120, No. 3. pp. 199-206.
@article{e7d0bdb1f83c4aeba960b630c012efd7,
title = "Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study",
abstract = "Objective: To evaluate the efficacy and safety of iloprost, a prostacyclin analog, administered intravenously in patients with Raynaud phenomenon secondary to systemic sclerosis. Design: Multicenter, randomized, parallel placebocontrolled, double-blind study. ■ Setting: University medical centers. ■ Patients: 131 patients with systemic sclerosis (101 women, 30 men) ages 20 to 79 years. ■ Intervention: Patients were randomly assigned to receive one of two parallel treatments of five daily sequential, 6-hour intravenous infusions of iloprost (0.5 to 2.0 ng/kg per min) or to receive a similar volume of placebo. Measurements: Frequency of Raynaud attacks, Raynaud severity score, physician's overall rating of treatment effect, and digital cutaneous lesion healing. ■ Results: Of the 131 patients enrolled, 126 completed the 5-day infusion and 114 (87{\%}) completed at least 6 weeks of follow-up. Sixty-four patients were randomly assigned to receive iloprost and 67 patients, to receive placebo. The mean weekly number of Raynaud attacks decreased 39.1{\%} with iloprost and 22.2{\%} with placebo (P= 0.005). In addition, the mean percentage of improvement in a global Raynaud severity score during the entire 9-week follow-up was greater in patients given iloprost (34.8{\%}) than in those receiving placebo (19.7{\%}) (P= 0.011). The physician's overall rating of treatment effect showed greater improvement with iloprost than with placebo at week 6 (52.4{\%} compared with 27.4{\%}; P = 0.008) and week 9 (60.9{\%} compared with 26.9{\%}; P <0.001). At week 3, 14.6{\%} more patients receiving iloprost had 50{\%} or more lesions heal compared with those given placebo (95{\%} Cl, 0.9{\%} to 30{\%}). During the infusion, 59 (92{\%}) of the patients receiving iloprost had one or more side effects compared with 38 (57{\%}) of the patients receiving placebo. ■ Conclusion: iloprost is effective for the short-term palliation of severe Raynaud phenomenon in patients with systemic sclerosis.",
author = "Fredrick Wigley and Wise, {Robert A} and Seibold, {James R.} and McCloskey, {Deborah A.} and Gregory Kujala and Medsger, {Thomas A.} and Steen, {Virginia D.} and John Varga and Sergio Jimenez and Maureen Mayes and Clements, {Philip J.} and Weiner, {Steven R.} and John Porter and Michael Ellman and Christopher Wise and Kaufman, {Lee D.} and John Williams and William Dole",
year = "1994",
month = "2",
day = "1",
language = "English (US)",
volume = "120",
pages = "199--206",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "3",

}

TY - JOUR

T1 - Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis

T2 - A multicenter, placebo-controlled, double-blind study

AU - Wigley, Fredrick

AU - Wise, Robert A

AU - Seibold, James R.

AU - McCloskey, Deborah A.

AU - Kujala, Gregory

AU - Medsger, Thomas A.

AU - Steen, Virginia D.

AU - Varga, John

AU - Jimenez, Sergio

AU - Mayes, Maureen

AU - Clements, Philip J.

AU - Weiner, Steven R.

AU - Porter, John

AU - Ellman, Michael

AU - Wise, Christopher

AU - Kaufman, Lee D.

AU - Williams, John

AU - Dole, William

PY - 1994/2/1

Y1 - 1994/2/1

N2 - Objective: To evaluate the efficacy and safety of iloprost, a prostacyclin analog, administered intravenously in patients with Raynaud phenomenon secondary to systemic sclerosis. Design: Multicenter, randomized, parallel placebocontrolled, double-blind study. ■ Setting: University medical centers. ■ Patients: 131 patients with systemic sclerosis (101 women, 30 men) ages 20 to 79 years. ■ Intervention: Patients were randomly assigned to receive one of two parallel treatments of five daily sequential, 6-hour intravenous infusions of iloprost (0.5 to 2.0 ng/kg per min) or to receive a similar volume of placebo. Measurements: Frequency of Raynaud attacks, Raynaud severity score, physician's overall rating of treatment effect, and digital cutaneous lesion healing. ■ Results: Of the 131 patients enrolled, 126 completed the 5-day infusion and 114 (87%) completed at least 6 weeks of follow-up. Sixty-four patients were randomly assigned to receive iloprost and 67 patients, to receive placebo. The mean weekly number of Raynaud attacks decreased 39.1% with iloprost and 22.2% with placebo (P= 0.005). In addition, the mean percentage of improvement in a global Raynaud severity score during the entire 9-week follow-up was greater in patients given iloprost (34.8%) than in those receiving placebo (19.7%) (P= 0.011). The physician's overall rating of treatment effect showed greater improvement with iloprost than with placebo at week 6 (52.4% compared with 27.4%; P = 0.008) and week 9 (60.9% compared with 26.9%; P <0.001). At week 3, 14.6% more patients receiving iloprost had 50% or more lesions heal compared with those given placebo (95% Cl, 0.9% to 30%). During the infusion, 59 (92%) of the patients receiving iloprost had one or more side effects compared with 38 (57%) of the patients receiving placebo. ■ Conclusion: iloprost is effective for the short-term palliation of severe Raynaud phenomenon in patients with systemic sclerosis.

AB - Objective: To evaluate the efficacy and safety of iloprost, a prostacyclin analog, administered intravenously in patients with Raynaud phenomenon secondary to systemic sclerosis. Design: Multicenter, randomized, parallel placebocontrolled, double-blind study. ■ Setting: University medical centers. ■ Patients: 131 patients with systemic sclerosis (101 women, 30 men) ages 20 to 79 years. ■ Intervention: Patients were randomly assigned to receive one of two parallel treatments of five daily sequential, 6-hour intravenous infusions of iloprost (0.5 to 2.0 ng/kg per min) or to receive a similar volume of placebo. Measurements: Frequency of Raynaud attacks, Raynaud severity score, physician's overall rating of treatment effect, and digital cutaneous lesion healing. ■ Results: Of the 131 patients enrolled, 126 completed the 5-day infusion and 114 (87%) completed at least 6 weeks of follow-up. Sixty-four patients were randomly assigned to receive iloprost and 67 patients, to receive placebo. The mean weekly number of Raynaud attacks decreased 39.1% with iloprost and 22.2% with placebo (P= 0.005). In addition, the mean percentage of improvement in a global Raynaud severity score during the entire 9-week follow-up was greater in patients given iloprost (34.8%) than in those receiving placebo (19.7%) (P= 0.011). The physician's overall rating of treatment effect showed greater improvement with iloprost than with placebo at week 6 (52.4% compared with 27.4%; P = 0.008) and week 9 (60.9% compared with 26.9%; P <0.001). At week 3, 14.6% more patients receiving iloprost had 50% or more lesions heal compared with those given placebo (95% Cl, 0.9% to 30%). During the infusion, 59 (92%) of the patients receiving iloprost had one or more side effects compared with 38 (57%) of the patients receiving placebo. ■ Conclusion: iloprost is effective for the short-term palliation of severe Raynaud phenomenon in patients with systemic sclerosis.

UR - http://www.scopus.com/inward/record.url?scp=0028147645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028147645&partnerID=8YFLogxK

M3 - Article

C2 - 7506013

AN - SCOPUS:0028147645

VL - 120

SP - 199

EP - 206

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 3

ER -